The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 237-241

  Fujita, Ken Ichi ^a   Sugiyama, Minako ^a   Akiyama, Yuko ^a   Ando, Yuichi ^b   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Drug drug interaction; Inhibition; Nilotinib; SN 38; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE 1A1; NILOTINIB;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG INTERACTION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; YOUNG ADULT;

EID: 78651083117     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1445-3     Document Type: Article

References (10)

1. L Zhang KS Reynolds P Zhao SM Huang 2010 Drug interactions evaluation: an integrated part of risk assessment of therapeutics Toxicol Appl Pharmacol 243 134 145 1:CAS:528:DC%2BC3cXit1Ogt7w%3D 10.1016/j.taap.2009.12.016 20045016
2. PW Manley SW Cowan-Jacob J Mestan 2005 Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Biochim Biophys Acta 1754 3 13 1:CAS:528:DC%2BD2MXhtlags7fI 16172030
3. E Weisberg P Manley J Mestan S Cowan-Jacob A Ray JD Griffin 2006 AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 1765 1769 1:CAS:528:DC%2BD28XlsFequr4%3D 10.1038/sj.bjc.6603170 16721371 (Pubitemid 43882564)
4. M Hazarika X Jiang Q Liu SL Lee R Ramchandani C Garnett MS Orr R Sridhara B Booth JK Leighton W Timmer R Harapanhalli R Dagher R Justice R Pazdur 2008 Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib Clin Cancer Res 14 5325 5331 1:CAS:528:DC%2BD1cXhtVKmsbzE 10.1158/1078-0432.CCR-08-0308 18765523
5. JB Singer Y Shou F Giles HM Kantarjian Y Hsu AS Robeva P Rae A Weitzman JM Meyer M Dugan OG Ottmann 2007 UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia Leukemia 21 2311 2315 1:CAS:528: DC%2BD2sXht1WgsbbE 10.1038/sj.leu.2404827 17611564 (Pubitemid 350019230)
6. K Araki K Fujita Y Ando F Nagashima W Yamamoto H Endo T Miya K Kodama M Narabayashi Y Sasaki 2006 Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 1255 1259 1:CAS:528:DC%2BD28XhtFemtbbN 10.1111/j.1349-7006. 2006.00321.x 16965601 (Pubitemid 44430653)
7. Copeland RA (2000) Enzymes: a practical introduction to structure, mechanism, and data analysis. Wiley, New York
8. K Ito HS Brown JB Houston 2004 Database analyses for the prediction of in vivo drug-drug interactions from in vitro data Br J Clin Pharmacol 57 473 486 1:CAS:528:DC%2BD2cXjslGmsb8%3D 10.1111/j.1365-2125.2003.02041.x 15025746 (Pubitemid 38519653)
9. C Tanaka OQ Yin V Sethuraman T Smith X Wang K Grouss H Kantarjian F Giles OG Ottmann L Galitz H Schran 2010 Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib Clin Pharmacol Ther 87 197 203 1:CAS:528:DC%2BC3cXhtFaltbY%3D 10.1038/clpt.2009.208 19924121
10. JF Gagne V Montminy P Belanger K Journault G Gaucher C Guillemette 2002 Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) Mol Pharmacol 62 608 617 1:CAS:528:DC%2BD38XmsVKmuro%3D 10.1124/mol.62.3.608 12181437 (Pubitemid 36329379)